Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB ...
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress ...
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is ...
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral ...
HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical data for the lead ...
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...
Hosted on MSN
Three’s a charm for EASL
EASL returns for a third straight home-and-away season with an expanded look to deliver a 42-game schedule which will be accessible globally through over 18 broadcast partners. PBA 2024 Philippine Cup ...
BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative ...
Data highlight RTY-406's dual ABCB4/BSEP mechanism and marks the first demonstration of proof of mechanism in a non-human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results